FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1747-1748 May 30, 2002 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Dalakas, M. C. PubMed Citation

To the Editor: Dalakas et al. (Dec. 27 issue)¹ report the efficacy of high-dose intravenous immune globulin for the treatment of stiff-person syndrome. Stiff-person syndrome is a devastating disorder, and evidence of the associated immunologic impairment began to emerge in the 1980s.² Over the next decade, it was confirmed that stiff-person syndrome was caused, in particular, by damage by an autoimmune mechanism.

Intravenous immune globulin is extraordinarily costly; thus, the current focus of interest among clinicians is not on the efficacy of this approach but, rather, on the timing of the treatment and its long-term outcome, including the duration of . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.